Table 3.
Clinical Characteristics by Index Drug Class—Age ≥18 y | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Index Drug Class–Stratified | ||||||||||
Total | Beta-lactam | Macrolide | Fluoroquinolone | Tetracycline | ||||||
Clinical and Disease Characteristics | na = 251 947 | na = 16 526 | na = 112 054 | na = 109 179 | na = 14 188 | |||||
No. | % | No. | % | No. | % | No. | % | No. | % | |
Pre-index (365-d) baseline comorbidities | ||||||||||
Charlson comorbidity index, mean (SD) | 0.88 | 1.53 | 1.04 | 1.68 | 0.69 | 1.32 | 1.04 | 1.66 | 0.98 | 1.59 |
Charlson comorbidity index | ||||||||||
0 | 150 354 | 59.7 | 9103 | 55.1 | 73 649 | 65.7 | 59 663 | 54.6 | 7939 | 56.0 |
1 | 49 989 | 19.8 | 3418 | 20.7 | 20 571 | 18.4 | 23 012 | 21.2 | 2988 | 21.1 |
2 | 23 540 | 9.3 | 1650 | 10.0 | 8790 | 7.8 | 11 671 | 10.7 | 1429 | 10.1 |
3+ | 28 064 | 11.1 | 2355 | 14.3 | 9044 | 8.1 | 14 833 | 13.6 | 1832 | 12.9 |
Individual CCI comorbidities | ||||||||||
Chronic pulmonary disease | 45 698 | 18.1 | 3436 | 20.8 | 17 139 | 15.3 | 22 134 | 20.3 | 2989 | 21.1 |
Cardiovascular disease | 42 237 | 16.7 | ||||||||
Cerebrovascular disease | 13 434 | 5.3 | 1090 | 6.6 | 4494 | 4.0 | 6995 | 6.4 | 855 | 6.0 |
Peripheral vascular disease | 12 687 | 5.0 | 1013 | 6.1 | 4151 | 3.7 | 6666 | 6.1 | 857 | 6.0 |
Congestive heart failure | 11 975 | 4.8 | 1087 | 6.6 | 3726 | 3.3 | 6289 | 5.8 | 873 | 6.2 |
Myocardial infarction | 4141 | 1.6 | 337 | 2.0 | 1318 | 1.2 | 2173 | 2.0 | 313 | 2.2 |
Diabetic disease | 37 610 | 14.5 | ||||||||
Diabetes | 28 856 | 11.0 | 2146 | 13.0 | 10 550 | 9.4 | 14 368 | 13.2 | 1792 | 12.6 |
Diabetes with chronic complications | 8754 | 3.5 | 642 | 3.9 | 3050 | 2.7 | 4528 | 4.1 | 534 | 3.8 |
Cancer | 14 571 | 5.8 | 1083 | 6.6 | 5261 | 4.7 | 7352 | 6.7 | 875 | 6.2 |
Renal disease | 8857 | 3.5 | 739 | 4.5 | 2974 | 2.7 | 4519 | 4.1 | 625 | 4.4 |
Chronic kidney disease | 8763 | 3.5 | 731 | 4.4 | 2948 | 2.6 | 4463 | 4.1 | 621 | 4.4 |
Mild liver disease | 7458 | 3.0 | 574 | 3.5 | 2773 | 2.5 | 3680 | 3.4 | 431 | 3.0 |
Dementia | 2744 | 1.1 | 242 | 1.5 | 696 | 0.6 | 1636 | 1.5 | 170 | 1.2 |
Metastatic cancer | 2426 | 1.0 | 204 | 1.2 | 683 | 0.6 | 1429 | 1.3 | 110 | 0.8 |
Peptic ulcer disease | 1761 | 0.7 | 150 | 0.9 | 653 | 0.6 | 841 | 0.8 | 117 | 0.8 |
Hemiplegia or paraplegia | 1207 | 0.5 | 138 | 0.8 | 424 | 0.4 | 575 | 0.5 | 70 | 0.5 |
End-stage renal disease | 1006 | 0.4 | 84 | 0.5 | 331 | 0.3 | 527 | 0.5 | 64 | 0.5 |
AIDSb | 595 | 0.2 | 31 | 0.2 | 229 | 0.2 | 309 | 0.3 | 26 | 0.2 |
Moderate or severe liver disease | 411 | 0.2 | 28 | 0.2 | 128 | 0.1 | 230 | 0.2 | 25 | 6.2 |
Other comorbidities | ||||||||||
Asthma | 22 611 | 9.0 | 1597 | 9.7 | 9383 | 8.4 | 10 185 | 9.3 | 1446 | 10.2 |
Arrhythmias | 22 163 | 8.8 | 1977 | 12.0 | 7588 | 6.8 | 10 896 | 10.0 | 1702 | 12.0 |
Data are presented as No. and % unless otherwise specified.
Abbreviations: CCI, Charlson comorbidity index; NEC, not elsewhere classified.
aAll clinical and disease characteristic analyses excluded patients with index drug (ceftriaxone and ciprofloxacin), due to low sample numbers.
bAll comparisons were statistically significant at P < .0001, except AIDS, which was .0004.